Scientific Health Development Partners

What Scientific Health Development Partners does

Scientific Health Development Partners (SHD Partners) is a Dallas-based boutique venture capital firm founded in 2006 that invests exclusively in early-stage, U.S.-based medical technology companies. The firm manages four successive funds (SHD Fund I, II, III, and IV) and targets innovative medical devices, diagnostics, therapeutics, and digital health solutions that address unmet clinical needs, require smaller capital rounds, and have attainable near-term value inflection points that could lead to an exit via IPO or acquisition. SHD positions its investment vehicles around Qualified Small Business tax advantages for limited partners while shielding them from short-term public market volatility.

SHD provides portfolio companies with capital, board-level participation, healthcare valuation expertise, and reimbursement analysis support. The firm has built a portfolio of 17+ active investments and 8 realized exits, including the Sight Sciences IPO (Nasdaq: SGHT). The leadership team comprises co-founders Philip Romano and Stuart Fitts as General Partners (Romano is the original sole outside investor in the Palmaz Stent, which created the multi-billion dollar coronary stent market), CEO and General Partner Andrew Offer (since 2007, CFA, board director across most active portfolio companies), and Principal R. Michael Schotzinger, PhD (since 2021, biomedical engineering background with prior venture experience at Cone Health Ventures, Catalyst Health Ventures, and Hatteras Venture Partners).

The firm's revenue mechanics are typical of a venture capital operation: management fees on committed/ invested fund capital, with returns generated through portfolio company exits (IPO or acquisition). Investment offerings are limited to qualified investors via private fund placements, with no publicly disclosed fee structure. Deal flow is generated through a 30+ year network of healthcare investors, entrepreneurs, and industry contacts, supplemented by participation in investor conferences such as RBC Capital Markets Healthcare, Wells Fargo Virtual Private MedTech Symposium, and Oppenheimer Healthcare MedTech & Services.

Name

Scientific Health Development Partners

Legal name

Scientific Health Development

Website

https://shdpartners.com

Company type

Private

Founded year

2006

Operating status

Operating

Headcount range

11–50 employees

Short description

SHD Partners is a Dallas-based boutique venture capital firm founded in 2006 that manages four funds (SHD I–IV) investing exclusively in early-stage U.S. MedTech companies, providing capital, board participation, and healthcare valuation expertise to portfolio companies developing innovative medical devices, diagnostics, and digital health solutions.

Ownership category

akta.pro rank

Product category

Healthcare Venture Capital

NAICS

Scientific Research and Development Services (5417), Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Services-Commercial Physical & Biological Research (8731)

akta.pro primary industry

Healthcare Access & Life Sciences Impact Funds (FSANAJAI)

Keywords

• Venture capital
• Medtech investing
• Early-stage funding
• Medical devices
• Healthcare investment

Headquarters

HQ city

Dallas

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Venture Capital Fund Management: SHD Partners generates returns through managing multiple investment funds (SHD Fund I, II, III, IV) focused on early-stage MedTech companies. Returns are generated through portfolio company exits via IPO or acquisition.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

Scientific Health Development (SHD) Partners is a Dallas-based venture capital firm that invests in early-stage U.S. medical technology companies addressing unmet clinical needs. The firm manages multiple dedicated investment funds (SHD Fund I, II, III, IV) that provide capital, strategic guidance, board participation, and operational support to portfolio companies developing medical devices, diagnostics, and digital health solutions with near-term value inflection points.

Product overview

SHD Partners operates as a venture capital firm managing multiple investment funds (SHD Fund I, II, III, and IV) focused exclusively on early-stage medical technology companies. Rather than offering a unified product platform, the firm's 'products' are its investment vehicles, which provide funding and operational support to portfolio companies developing medical devices, diagnostics, and digital health solutions. The funds target companies with innovative technologies addressing unmet clinical needs, requiring smaller funding amounts with near-term value inflection points leading to potential exits.

Differentiator

Problem solved

Functional benefit

Products and services

• SHD Fund I First venture capital fund managed by SHD Partners, focused on early-stage MedTech investments in innovative medical technologies with near-term value inflection points.
• SHD Fund II

Quantifiable outcome

• SHD Fund I investment in Sight Sciences resulted in IPO (Nasdaq: SGHT)
• +2 more outcomes

Segments1 record

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Partnerships

Two partnerships are on record, tiered flagship and core.

• Mountaineer BiosciencesflagshipStrategic or Co-development Partner · 22 April 2026Mindera Health (SHD portfolio company) partnered with Mountaineer Biosciences to launch Subtilitas, a precision translational medicine platform for dermatology and immunology that integrates non-invasive skin sampling, advanced molecular profiling, and AI/ML.
• HealthMedcoreStrategic or Co-development Partner · 18 June 2025Podimetrics (SHD portfolio company) partnered with HealthMed to expand access to its SmartMat Program, a diabetes solution that enhances chronic care management.

Scale indicators5 records

Recent moves6 records

Expansion highlights5 records

Direct peers

• 3x5 Partners: Healthcare and life sciences venture firm that led Koya Medical's $26M Series B alongside SHD. Operates a similar early-to-growth-stage MedTech strategy, providing a directly comparable specialist healthcare investor.
• Mountain Group Partners: Healthcare-focused VC firm that co-invested with SHD in Mindera Health's $14M convertible note. Operates a similar early-stage MedTech thesis and has co-led rounds with SHD in the same portfolio companies, making it a closely comparable direct peer.
• Hatteras Venture Partners: Early-stage healthcare venture firm specifically referenced in SHD's own management team background (Schotzinger interned there). Invests in healthcare companies across similar stages and therapeutic areas, making it a directly comparable specialist MedTech VC.
• Catalyst Health Ventures: Early-stage healthcare VC firm explicitly cited in SHD's principal's prior work experience. Catalyst focuses on early-stage medical device, digital health, and diagnostic opportunities with a thesis similar to SHD's capital-efficient MedTech strategy.
• Cone Health Ventures: Healthcare-focused venture firm where SHD's principal previously worked. Both firms target early-stage MedTech companies with smaller funding requirements, providing a directly comparable peer in the niche specialist VC segment.
• Cadence Healthcare Ventures: Healthcare-focused venture firm that participated in Koya Medical's $26M Series B alongside SHD. Targets early-stage MedTech opportunities with similar check sizes and operating support models.
• Asahi Kasei Ventures: Corporate venture arm investing in healthcare and MedTech. Co-invested in Koya Medical with SHD and operates a comparable early-stage healthcare investment thesis across similar stages.
• Arboretum Ventures: Healthcare-focused VC firm investing in medical devices, diagnostics, and healthcare services. Co-invested with SHD in Koya Medical's Series B and operates a comparable early-stage MedTech mandate.

Broad incumbents

• Versant Ventures: Established healthcare-focused venture firm with multiple funds across medical devices, biopharma, and healthcare services. Operates in a comparable MedTech venture niche but at a much larger scale than SHD, representing a broad incumbent peer.
• OrbiMed Advisors: One of the largest healthcare-dedicated investment firms globally, investing across MedTech, biopharma, and diagnostics. As a broad incumbent, it competes for the same types of deals as SHD but with much larger fund sizes and broader sector coverage.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/scientific-health-development

Revenue estimate

Valuation estimate

Number of profiles

Profiles4 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments26 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Scientific Health Development Partners